MPM: NextPoint Therapeutics Raises $42.5M; Closes $122.5M Series B Financing

NextPoint Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, raised $42.5M in Series B extension funding. The round, which brought the total amount of Series B to $122.5M, was led by Catalio Capital Management. As part of the financing, R. Jacob Vogelstein, PhD, [...]The post NextPoint Therapeutics Raises $42.5M; Closes $122.5M Series B Financing appeared first on FinSMEs.